Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Consensus Price Target from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.83.

A number of analysts have commented on the company. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Wednesday. Finally, Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. increased its position in shares of Altimmune by 12.9% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after purchasing an additional 2,687 shares during the last quarter. Creative Planning grew its position in Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after buying an additional 3,132 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares during the last quarter. Larson Financial Group LLC bought a new position in Altimmune in the third quarter worth approximately $31,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Altimmune by 30.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock worth $179,000 after acquiring an additional 6,339 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

Shares of Altimmune stock opened at $6.99 on Friday. Altimmune has a 1 year low of $5.28 and a 1 year high of $14.84. The firm’s 50-day moving average is $7.66 and its 200 day moving average is $7.17. The stock has a market cap of $497.13 million, a price-to-earnings ratio of -4.51 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the company earned ($0.39) EPS. On average, equities analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.